Arsanis Aktie
WKN DE: A2PFVY / ISIN: US98420X1037
10.06.2025 14:53:13
|
FDA Grants Fast Track Designation To X4 Pharma's Mavorixafor For Chronic Neutropenia
(RTTNews) - X4 Pharmaceuticals, Inc. (XFOR), Tuesday said that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia (CN).
A Phase 3 study of mavorixafor in certain primary CN conditions is underway. Topline data from Phase 3 4WARD study in CN are expected in late 2026.
Mavorixafor is already approved in 2024 for the treatment of WHIM syndrome, a rare genetic disorder.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Arsanis Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Arsanis Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Arsanis Inc Registered Shs | 0,14 | -23,53% |
|